Contains the active ingredient trastuzumab emtansine (rch)
Consumer Medicine Information
WARNING: Do not substitute Kadcyla for or with trastuzumab.
In order to prevent medication errors, check the vial labels to ensure the medicine
being prepared and administered is Kadcyla (trastuzumab emtansine) and not trastuzumab
What is in this leaflet
This leaflet answers some common questions about Kadcyla.
It does not contain all the available information. It does not take the place of
talking to your pharmacist or doctor.
All medicines have risks and benefits. Your doctor has weighed the risks of you taking
Kadcyla against the benefits they expect it will have for you.
If you have any concerns about taking this medicine, ask your doctor or pharmacist.
Keep this leaflet.
You may need to read it again.
What Kadcyla is used for
Kadcyla contains an active ingredient called trastuzumab emtansine.
Kadcyla belongs to a group of medicines known as anti-neoplastic (or anti-cancer)
Kadcyla is made up of two substances:
trastuzumab - a monoclonal antibody which recognises and attaches to a protein called
human epidermal growth factor receptor 2 (HER2). HER2 is found in large amounts on
the surface of some cancer cells.
emtansine - an anti-cancer substance.
Kadcyla is designed to target and deliver the anti-cancer emtansine directly inside
HER2-positive cancer cells to stop the growth and spread of the cancer cells.
Kadcyla is used to treat people with advanced or metastatic (spreading) breast cancer.
It is only used in patients whose tumour has tested positive to HER2. You may have
previously received HER2 targeted therapies.
Ask your doctor if you have any questions about why this medicine has been prescribed
for you. Your doctor may have given it for another reason.
This medicine is available only with a doctor's prescription.
Before you are given Kadcyla
Before you are given it
Tell your doctor if:
you have had a serious infusion-related reaction to trastuzumab (HERCEPTIN)
you have a history of heart problems
Your doctor will monitor your heart function closely before and during your treatment
you have any breathing or lung problems
you have liver problems
you have bleeding problems
you are receiving anti-coagulant treatment (blood thinning medications) e.g. warfarin,
heparin or low molecular weight heparin
Kadcyla can lower the number of platelets in your blood. Platelets help your blood
to clot so you might get unexpected bleeding (such as nose bleeds, bleeding from gums).
Your doctor or nurse will monitor your platelet levels during your treatment with
you are allergic to any other medicines or any other substances such as foods, preservatives
Allergic and/or anaphylactic reactions can occur with Kadcyla treatment (known as
infusion related reactions). Your doctor or nurse will check for side effects during
your infusion. See "side effects" for symptoms to look out for.
you are pregnant or intend to become pregnant
Do not use Kadcyla if you are pregnant. Kadcyla may be harmful to your unborn baby.
Your doctor will advise you about using effective contraception to avoid becoming
pregnant while you are being treated with Kadcyla and for 7 months after stopping
treatment. It is not known if Kadcyla affects the ability of a woman to become pregnant.
Discuss any future child bearing plans with your doctor before starting Kadcyla.
you are breast-feeding or plan to breast-feed
It is not known if Kadcyla passes into breast milk. It is recommended that you discontinue
breast-feeding while you are being treated with Kadcyla and not start breast-feeding
until 7 months after completing Kadcyla treatment.
If you have not told your doctor about any of the above, tell them before you are
Use in children
The safety and effectiveness of Kadcyla in children under 18 years of age have not
Taking other medicines
Tell your doctor if you are taking any other medicines including any that you have
bought without a prescription from a pharmacy, supermarket or health food shop.
The following medicines may interfere with Kadcyla;
Oral antifungal medications, e.g. ketoconazole, itraconazole, voriconazole
Some antibiotics used to treat bacterial infections, e.g. clarithromycin, telithromycin
Medicines used to treat hepatitis, e.g. telaprevir, boceprevir
Medicines used to treat depression e.g. nefazodone
Your doctor and pharmacist have more information on medicines to be careful with or
avoid while receiving Kadcyla.
How Kadcyla is given
Follow all directions given to you by your doctor or pharmacist carefully.
They may differ from the information contained in this leaflet.
Kadcyla is prepared by a healthcare professional and will be given in a hospital or
clinic by a doctor or nurse.
Kadcyla is given by a slow drip into a vein (intravenous (IV) infusion) once every
The first infusion will be given over 90 minutes. If the first infusion is well tolerated,
your drip time may be shortened to 30 minutes.
The number of infusions you will be given depends on how you respond to treatment.
If you miss a dose
As Kadcyla is given under the supervision of your doctor, you are unlikely to miss
a dose. However, if you forget or miss your appointment to receive Kadcyla, make another
appointment as soon as possible. Do not wait for your next planned appointment. Your
doctor will decide when your next dose of Kadcyla will be.
If you are given too much (overdose)
As Kadcyla is given under the supervision of your doctor it is unlikely that you will
be given too much. However, if you experience any side effects after being given Kadcyla,
tell your doctor or nurse immediately
While you are receiving Kadcyla
Things you must do
Tell all doctors, dentists and pharmacists who are treating you that you are receiving
Tell your doctor if you become pregnant or intend to start a family while receiving
Be sure to keep all of your appointments with your doctor so that your progress can
Your doctor will perform regular tests to monitor for;
Things you must not do
Do not stop your Kadcyla treatment without talking to your doctor first.
Tell your doctor if you feel that Kadcyla is not helping your condition.
Do not take any other medicines, whether they require a prescription or not, without
first telling your doctor or consulting with a pharmacist.
Things to be careful of
Be careful driving or operating machinery until you know how Kadcyla affects you.
It is not known whether Kadcyla may affect your ability to drive or operate machinery.
If you experience infusion-related reactions do not drive and use machines until symptoms
Tell your doctor as soon as possible if you do not feel well while you are receiving
Kadcyla helps most people with HER2 positive metastatic (spreading) breast cancer
but it may have some unwanted side effects in some people.
All medicines can have side effects. Sometimes they are serious, most of the time
they are not. You may need medical treatment if you get some of the side effects.
Ask your doctor or pharmacist to answer any questions you may have.
During an infusion
Tell your doctor or nurse immediately if you notice any of the following while receiving
an infusion (particularly during the first infusion):
swelling of your face, lips, tongue or throat with difficulty breathing
swelling of other parts of your body such as your hands or feet
shortness of breath, wheezing or trouble breathing
abnormal or irregular heartbeat
rash, itching or hives on the skin
flushing (warm, red) skin
pain or swelling at site of injection
feeling sick (nausea) or vomiting, diarrhoea
pain or discomfort (including stomach pain, back pain, chest or neck pain)
fever or chills
fatigue or tiredness
These may be serious side effects. You may require urgent medical attention.
After an infusion
Tell your doctor immediately or go to Accident and Emergency at your nearest hospital
if you notice any of the following:
any of the side effects listed above;
swelling of ankles or legs
weight gain of more than 2 kilograms in 24 hours
dizziness or fainting
shortness of breath, especially when lying down or being woken from your sleep
jaundice (your skin and whites of your eyes look yellow)
rash, itching or hives on the skin
loss of appetite
Tell your doctor or nurse as soon as possible if you notice any of the following:
getting tired more easily after light physical activity, such as walking
insomnia (difficulty sleeping)
weakness, soreness in muscles and/or joints
numbness or weakness of arms and legs bleeding or bruising more easily than normal
nose bleeds feeling dizzy, tired, looking pale
flu and/or cold like symptoms, frequent infections such as fever, severe chills, sore
throat or mouth ulcers
taste disturbance or loss of taste
eye problems such as producing more tears, swollen runny eyes or conjunctivitis (discharge
with itching of the eyes and crusty eyelids)
This is not a complete list of all possible side effects. Your doctor or pharmacist
has a more complete list. Others may occur in some people and there may be some side
effects not yet known.
Tell your doctor if you notice anything else that is making you feel unwell, even
if it is not on this list.
Ask your doctor, nurse or pharmacist if you don't understand anything in this list.
Do not be alarmed by this list of possible side effects. You may not experience any
Kadcyla will be stored in the pharmacy or on the hospital ward in a refrigerator at
a temperature between 2°C and 8°C. Kadcyla solution should not be frozen.
Kadcyla is supplied as a single use vial and is available in two strengths, 100 mg
and 160 mg.
What Kadcyla looks like
Kadcyla is a white to off-white powder which is dissolved in sterile water before
After dissolving, the Kadcyla solution should appear as a clear colourless to pale
Each vial of Kadcyla contains 100 mg or 160 mg of the active ingredient, trastuzumab
It also contains;
The trastuzumab protein is made using Chinese hamster ovary cells.
Kadcyla is distributed in Australia by:
Roche Products Pty Limited
ABN 70 000 132 865
Level 8, 30-34 Hickson Road
Sydney NSW 2000
Medical enquiries: 1800 233 950
Please check with your pharmacist for the latest Consumer Medicine Information.
Australian Registration Numbers
100 mg: AUST R 201621
160 mg: AUST R 201622
This leaflet was prepared on 12 December 2017